Distinct Effects of p38α Deletion in Myeloid Lineage and Gut Epithelia in Mouse Models of Inflammatory Bowel Disease

Gastroenterology

Volumn 138, Issue 4, 2010, Pages

  Otsuka, Motoyuki ^a   Kang, Young Jun ^a   Ren, Jianlin ^b   Jiang, Huiping ^c   Wang, Yinbin ^d   Omata, Masao ^e   Han, Jiahuai ^a,f  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b XIAMEN UNIVERSITY   (China)

^c BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF TOKYO   (Japan)

^f BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

Author keywords

Colitis; Knockout Mice; p38

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; DEXTRAN SULFATE; DIBENZAZEPINE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE 11; MITOGEN ACTIVATED PROTEIN KINASE 12; MITOGEN ACTIVATED PROTEIN KINASE 13; MITOGEN ACTIVATED PROTEIN KINASE 14; TRINITROBENZENESULFONIC ACID; IMIDAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; SECRETASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; CELL DISRUPTION; CELL INFILTRATION; CELL SPECIFICITY; COLITIS; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE COURSE; DRUG INHIBITION; ENTERITIS; EXPERIMENTAL MODEL; EXPERIMENTAL MOUSE; INFLAMMATION; INTESTINE EPITHELIUM CELL; KNOCKOUT MOUSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; WILD TYPE; ANIMAL; ANTIBODY SPECIFICITY; C57BL MOUSE; CELL DIFFERENTIATION; CELL PROLIFERATION; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; GENETICS; INTESTINE MUCOSA; MOUSE MUTANT; PATHOLOGY; PHYSIOLOGY;

AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; CELL DIFFERENTIATION; CELL PROLIFERATION; IMIDAZOLES; INFLAMMATORY BOWEL DISEASES; INTESTINAL MUCOSA; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MITOGEN-ACTIVATED PROTEIN KINASE 14; MYELOID CELLS; ORGAN SPECIFICITY; PYRIDINES;

EID: 77949841924     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2010.01.005     Document Type: Article

References (35)

1. Loftus C.G., Loftus Jr. E.V., Harmsen W.S., et al. Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota, 1940-2000. Inflamm Bowel Dis 13 (2007) 254-261
2. Podolsky D.K. Inflammatory bowel disease. N Engl J Med 347 (2002) 417-429
3. Xavier R.J., and Podolsky D.K. Unravelling the pathogenesis of inflammatory bowel disease. Nature 448 (2007) 427-434
4. Strober W., Fuss I., and Mannon P. The fundamental basis of inflammatory bowel disease. J Clin Invest 117 (2007) 514-521
5. Sartor R.B. Targeting enteric bacteria in treatment of inflammatory bowel diseases: why, how, and when. Curr Opin Gastroenterol 19 (2003) 358-365
6. O'Neill L.A. Targeting signal transduction as a strategy to treat inflammatory diseases. Nat Rev Drug Discov 5 (2006) 549-563
7. Han J., Lee J.-D., Bibbs L., et al. A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. Science 265 (1994) 808-811
8. Kumar S., Boehm J., and Lee J.C. p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases. Nat Rev Drug Discov 2 (2003) 717-726
9. Waetzig G.H., Seegert D., Rosenstiel P., et al. p38 mitogen-activated protein kinase is activated and linked to TNF-alpha signaling in inflammatory bowel disease. J Immunol 168 (2002) 5342-5351
10. Waetzig G.H., and Schreiber S. Review article: mitogen-activated protein kinases in chronic intestinal inflammation-targeting ancient pathways to treat modern diseases. Aliment Pharmacol Ther 18 (2003) 17-32
11. Hommes D., van den B.B., Plasse T., et al. Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease. Gastroenterology 122 (2002) 7-14
12. Schreiber S., Feagan B., D'Haens G., et al. Oral p38 mitogen-activated protein kinase inhibition with BIRB 796 for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol 4 (2006) 325-334
13. Hollenbach E., Vieth M., Roessner A., et al. Inhibition of RICK/nuclear factor-kappaB and p38 signaling attenuates the inflammatory response in a murine model of Crohn disease. J Biol Chem 280 (2005) 14981-14988
14. Hollenbach E., Neumann M., Vieth M., et al. Inhibition of p38 MAP kinase- and RICK/NF-kappaB-signaling suppresses inflammatory bowel disease. FASEB J 18 (2004) 1550-1552
15. ten Hove T., van den Blink B., Pronk I., et al. Dichotomal role of inhibition of p38 MAPK with SB 203580 in experimental colitis. Gut 50 (2002) 507-512
16. Malamut G., Cabane C., Dubuquoy L., et al. No evidence for an involvement of the p38 and JNK mitogen-activated protein in inflammatory bowel diseases. Dig Dis Sci 51 (2006) 1443-1453
17. Kang Y.J., Chen J., Otsuka M., et al. Macrophage deletion of p38alpha partially impairs lipopolysaccharide-induced cellular activation. J Immunol 180 (2008) 5075-5082
18. Perdiguero E., Ruiz-Bonilla V., Gresh L., et al. Genetic analysis of p38 MAP kinases in myogenesis: fundamental role of p38alpha in abrogating myoblast proliferation. EMBO J 26 (2007) 1245-1256
19. Kim C., Sano Y., Todorova K., et al. The kinase p38 alpha serves cell type-specific inflammatory functions in skin injury and coordinates pro- and anti-inflammatory gene expression. Nat Immunol 9 (2008) 1019-1027
20. Lipkin M. Cell proliferation in gastrointestinal disease. Natl Cancer Inst Monogr 30 (1969) 199-207
21. Bell B., Deschner E., Almy T.P., et al. Patterns of cell proliferation in gastrointestinal disease. Dis Colon Rectum 10 (1967) 107-111
22. Engel F.B., Schebesta M., Duong M.T., et al. p38 MAP kinase inhibition enables proliferation of adult mammalian cardiomyocytes. Genes Dev 19 (2005) 1175-1187
23. Hui L., Bakiri L., Mairhorfer A., et al. p38alpha suppresses normal and cancer cell proliferation by antagonizing the JNK-c-Jun pathway. Nat Genet 39 (2007) 741-749
24. Ventura J.J., Tenbaum S., Perdiguero E., et al. p38alpha MAP kinase is essential in lung stem and progenitor cell proliferation and differentiation. Nat Genet 39 (2007) 750-758
25. Madison B.B., Dunbar L., Qiao X.T., et al. Cis elements of the villin gene control expression in restricted domains of the vertical (crypt) and horizontal (duodenum, cecum) axes of the intestine. J Biol Chem 277 (2002) 33275-33283
26. Specian R.D., and Oliver M.G. Functional biology of intestinal goblet cells. Am J Physiol 260 (1991) C183-C193
27. Neurath M.F., Pettersson S., Meyer zum Buschenfelde K.H., et al. Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-kappa B abrogates established experimental colitis in mice. Nat Med 2 (1996) 998-1004
28. van Es J.H., van Gijn M.E., Riccio O., et al. Notch/gamma-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature 435 (2005) 959-963
29. Fre S., Huyghe M., Mourikis P., et al. Notch signals control the fate of immature progenitor cells in the intestine. Nature 435 (2005) 964-968
30. Jensen J., Pedersen E.E., Galante P., et al. Control of endodermal endocrine development by Hes-1. Nat Genet 24 (2000) 36-44
31. Yang Q., Bermingham N.A., Finegold M.J., et al. Requirement of Math1 for secretory cell lineage commitment in the mouse intestine. Science 294 (2001) 2155-2158
32. Mikkola I., Bruun J.A., Bjorkoy G., et al. Phosphorylation of the transactivation domain of Pax6 by extracellular signal-regulated kinase and p38 mitogen-activated protein kinase. J Biol Chem 274 (1999) 15115-15126
33. Greten F.R., Eckmann L., Greten T.F., et al. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118 (2004) 285-296
34. Eckmann L., Nebelsiek T., Fingerle A.A., et al. Opposing functions of IKKbeta during acute and chronic intestinal inflammation. Proc Natl Acad Sci U S A 105 (2008) 15058-15063
35. Thornton T.M., Pedraza-Alva G., Deng B., et al. Phosphorylation by p38 MAPK as an alternative pathway for GSK3beta inactivation. Science 320 (2008) 667-670